News

InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. FDA's NCTR have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues.

InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. FDA's NCTR have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues.

InSphero, a leading innovator in 3D Cell Culture and Organ-on-Chip technology, has announced a new collaboration with Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, and the Université Libre de Bruxelles (ULB) Center for Diabetes Research.

InSphero AG is pleased to announce its exclusive commercialization of TrueCardium® Cardiac Organoid Platform in partnership with Genome Biologics.

In a notable collaboration that underscores the power of innovation in drug discovery, SanaGen and InSphero, alongside the renowned Sanquin research institute, have been awarded a 1.3 million euro grant for the ambitious project NOCAAVAAT.

InSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of MASH Drug Discovery.

InSphero, the global leader in 3D in vitro technology for drug safety and efficacy testing, is proud to announce the appointment of Paul Clémençon, MBA as the new Chief Business Officer (CBO), further strengthening its Executive team.

The Physicians Committee for Responsible Medicine and InSphero are pleased to announce the winners of the HUMAIN Award 2023. The initiative recognizes researchers working to expand the access to and accelerate the uptake of human-specific non-animal approaches.

InSphero AG, the global leader in 3D cell culture technologies and organ-on-chip systems for drug discovery, and ATCC, the world’s premier biological materials management and standards organization, will work together to introduce new paradigms in the rapidly evolving field of 3D cell-based oncology research.

InSphero announces the launch of the MASH CALL Initiative for fast and reliable identification and comparison of therapeutic candidates for the clinical treatment of MASH.

InSphero Launches New Website Showcasing “The Model of Excellence™” Empowering Breakthroughs in 3D In Vitro Therapies

InSphero and Darwin Microfluidics signed distribution agreement to facilitate purchasing InSphero’s 3D in vitro products within the European Union Zurich, Switzerland – September 7, 2023